Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas

Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas

Leiomyosarcoma (LMS) is a rare, aggressive, mesenchymal tumor. Subsets of LMS have been identified to harbor genomic alterations associated with homologous recombination deficiency (HRD); particularly alterations in BRCA2. Whereas genomic loss of heterozygosity (gLOH) has been used as a surrogate ma...

Full description

Bibliographic Details
Main Authors: Bennett, M.P (Author), Chen, J.L (Author), Elvin, J.A (Author), Graim, K. (Author), Hays, J.L (Author), Jin, D.X (Author), Miles, W.O (Author), Millis, S.Z (Author), Seligson, N.D (Author), Tang, J. (Author)
Format: Article
Language:English
Published: Nature Research 2022
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items